Research Article

You have full text access to this OnlineOpen article

Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease†

  1. Nilesh R. Ghugre1,2,
  2. Ignacio Gonzalez-Gomez3,
  3. Ellen Butensky4,
  4. Leila Noetzli1,
  5. Roland Fischer5,6,
  6. Roger Williams7,
  7. Paul Harmatz4,
  8. Thomas D. Coates3,8,
  9. John C. Wood1,2,*

Article first published online: 18 MAY 2009

DOI: 10.1002/ajh.21456

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 8, pages 480–483, August 2009

Additional Information

How to Cite

Ghugre, N. R., Gonzalez-Gomez, I., Butensky, E., Noetzli, L., Fischer, R., Williams, R., Harmatz, P., Coates, T. D. and Wood, J. C. (2009), Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am. J. Hematol., 84: 480–483. doi: 10.1002/ajh.21456

Author Information

  1. 1

    Division of Cardiology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California

  2. 2

    Department of Radiology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California

  3. 3

    Department of Pathology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California

  4. 4

    Department of Gastroenterology and Nutrition, Children's Hospital and Research Center at Oakland, Oakland, California

  5. 5

    Pediatric Clinical Research Center, Children's Hospital and Research Center at Oakland, Oakland, California

  6. 6

    Department of Pediatric Hematology-Oncology, University Clinic Hamburg-Eppendorf, Hamburg, Germany

  7. 7

    Department of Pathology, Children's Hospital and Research Center at Oakland, Oakland, California

  8. 8

    Division of Hematology-Oncology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California

*Division of Cardiology, Mailstop #34, Children's Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027-0034

  1. †

    Conflict of Interest: Dr. Wood, Dr. Coates, and Dr. Harmatz have research funding from Novartis and had received speakers honoraria from Novartis and Apotex.

Publication History

  1. Issue published online: 24 JUL 2009
  2. Article first published online: 18 MAY 2009
  3. Accepted manuscript online: 18 MAY 2009 12:00AM EST
  4. Manuscript Accepted: 13 MAY 2009
  5. Manuscript Revised: 12 MAY 2009
  6. Manuscript Received: 20 OCT 2008

Funded by

  • National Institutes of Health (General Clinical Research Center). Grant Number: RR00043-43
  • Pediatric Clinical Research Center at the Children's Hospital & Research Center, Oakland. Grant Number: M01 RR01271
  • Center for Disease Control (Thalassemia Center). Grant Number: U27/CCU922106
  • Department of Pediatrics at Children's Hospital Los Angeles (CHLA)
  • National Heart Lung and Blood Institute of the National Institutes of Health. Grant Number: 1 R01 HL75592-01A1
  • National Institute for Diabetes, Digestion, and Kidney Disease. Grant Number: R01 DK057778
  • Saban Research Institute at CHLA

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (190K)

References

  • 1
    Darbari DS,Kple-Faget P,Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858–863.
  • 2
    Sonakul D,Pacharee P,Thakerngpol K. Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Orig Artic Ser 1988; 23: 157–176.
  • 3
    Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38: 57–62.
  • 4
    Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007; 82: 1128–1131.
  • 5
    Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007; 82: 1136–1139.
  • 6
    Vichinsky E,Butensky E,Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80: 70–74.
  • 7
    Walter PB,Fung EB,Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135: 254–263.
  • 8
    Fung EB,Harmatz PR,Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135: 574–582.
  • 9
    Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46: 554–557.
  • 10
    Sohn YS,Breuer W,Munnich A, et al. Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications. Blood 2008; 111: 1690–1699.
  • 11
    Kattamis A,Papassotiriou I,Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809–812.
  • 12
    Kearney SL,Nemeth E,Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57–63.
  • 13
    Mcnamara L,Macphail AP,Mandishona E, et al. Non-transferrin-bound iron and hepatic dysfunction in African dietary iron overload. J Gastroenterol Hepatol 1999; 14: 126–132.
  • 14
    Harmatz P,Butensky E,Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76–79.
  • 15
    Fung EB,Harmatz PR,Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 2008; 48: 1971–1980.
  • 16
    Schein A,Enriquez C,Coates TD, et al. Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis. J Magn Reson Imaging 2008; 28: 698–704.
  • 17
    Fung EB,Harmatz P,Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255–265.
  • 18
    Wood JC,Tyszka JM,Ghugre N, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 2004; 103: 1934–1936.
  • 19
    Nishina S,Hino K,Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226–238.
  • 20
    Takeo M,Kobayashi Y,Fujita N, et al. Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 562–569.
  • 21
    Fujita N,Sugimoto R,Takeo M, et al. Hepcidin expression in the liver: Relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97–104.
  • 22
    Gabutti V,Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol 1994; 7: 919–940.
  • 23
    Wood J,Aguilar M,Otto-Duessel M, et al. Influence of iron chelation therapy on R1 and R2 calibration curves in gerbil liver and heart. Magn Reson Med 2008; 60: 82–89.
  • 24
    Wood JC,Otto-Duessel M,Gonzalez I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006; 148: 272–280.
  • 25
    Butensky E,Fischer R,Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005; 123: 146–152.
  • 26
    Deugnier YM,Loreal O,Turlin B, et al. Liver pathology in genetic hemochromatosis: A review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992; 102: 2050–2059.
Get PDF (190K)